Market Overview:
The global haemorrhagic stroke drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of haemorrhagic strokes, rising geriatric population, and technological advancements in the field of haemorrhagic stroke drugs. The global haemorrhagic stroke drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into antihypertensives, anticoagulants, diuretics, anticonvulsants and others. Antihypertensives are expected to account for a major share in this market due to their high usage for treating hypertension-related strokes. On the basis of application, hospitals are expected to account for a major share in this market due to increased awareness about early diagnosis and treatment options for haemorrhagic strokes among healthcare professionals as well as patients across regions.
Product Definition:
Haemorrhagic stroke drugs are medications that help to reduce the risk of haemorrhagic strokes. These drugs work by decreasing the blood pressure and helping to keep the blood vessels open. They can also help to prevent blood clots from forming.
Antihypertensives:
Antihypertensives is a drug class that helps to lower blood pressure. The main target population for antihypertensives are those who have been recently diagnosed with hypertension or those at risk of developing it. Antihypertensive drugs can be used in two ways, either as a single drug to control high blood pressure or as part of a combination therapy with other anti-hypertensive agents and lifestyle modification.
Anticoagulants:
Anticoagulants are used to lower the blood clotting tendency. They work by interference with the coagulation cascade, which is initiated by thromboxane A2. Anticoagulants are most commonly used in patients suffering from lifestyle diseases such as diabetes and obesity, who smoke cigarettes, and also in patients undergoing surgery.
Application Insights:
Based on the application, the global market is segmented into hospitals, clinics and other medical facilities, and others. Hospitals held the largest share in 2017 owing to factors such as a large patient base that mandates a high number of hospital admissions for stroke treatment. Furthermore, hospitals have established departments dedicated to treat patients with haemorrhagic stroke thus providing an opportunity for vendors to penetrate this market at a larger scale.
The clinics and other medical facilities segment is expected register fastest CAGR over the forecast period due to increasing incidences of cardiovascular diseases coupled with rising awareness about early diagnosis & effective treatment procedures. According to WHO¢â‚¬â„¢s estimates around 1 in 3 deaths occur due to CVD globally which accounts for approximately 6th leading cause of death worldwide; however, these statistics are anticipatedto increase by 2030 accounting for 7th position if no action is taken against it.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. This can be attributed to the presence of a large patient pool, favorable government initiatives, and increasing healthcare expenditure. For instance, as per an article published by WebMD on January 2019 titled ‘5 Things You Need To Know About The New FDA Approval’ it was stated that ‘FDA has approved Dapagliflozin for sale OTC under the brand name Prilosec OTC for adults with hypertension and diabetes who have had a stroke or TIA within 7 days.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels coupled with growing awareness about early diagnosis & treatment of this condition. Moreover, increasing medical tourism due to affordability factor is also anticipated boost regional growth during future years (2030).
Growth Factors:
- Increasing incidence of haemorrhagic stroke
- Growing awareness about haemorrhagic stroke and its risk factors
- Rising demand for better and more effective treatment options for haemorrhagic stroke
- Technological advancements in the field of haemorrhagic stroke drugs and treatments
- Availability of government funding for research on new drugs and treatments for haemorrhagic stroke
Scope Of The Report
Report Attributes
Report Details
Report Title
Haemorrhagic Stroke Drugs Market Research Report
By Type
Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants, Others
By Application
Hospitals, Clinics, Others
By Companies
Baxter, Novartis, Pfizer, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Haemorrhagic Stroke Drugs Market Report Segments:
The global Haemorrhagic Stroke Drugs market is segmented on the basis of:
Types
Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Novartis
- Pfizer
- Sanofi
Highlights of The Haemorrhagic Stroke Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antihypertensives
- Anticoagulants
- Diuretics
- Anticonvulsants
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Haemorrhagic Stroke Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Haemorrhagic stroke drugs are medications that can help to prevent or reduce the severity of a hemorrhagic stroke.
Some of the major companies in the haemorrhagic stroke drugs market are Baxter, Novartis, Pfizer, Sanofi.
The haemorrhagic stroke drugs market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Haemorrhagic Stroke Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Haemorrhagic Stroke Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Haemorrhagic Stroke Drugs Market - Supply Chain
4.5. Global Haemorrhagic Stroke Drugs Market Forecast
4.5.1. Haemorrhagic Stroke Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Haemorrhagic Stroke Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Haemorrhagic Stroke Drugs Market Absolute $ Opportunity
5. Global Haemorrhagic Stroke Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
5.3.1. Antihypertensives
5.3.2. Anticoagulants
5.3.3. Diuretics
5.3.4. Anticonvulsants
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Haemorrhagic Stroke Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Haemorrhagic Stroke Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Haemorrhagic Stroke Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Haemorrhagic Stroke Drugs Demand Share Forecast, 2019-2026
9. North America Haemorrhagic Stroke Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
9.7.1. Antihypertensives
9.7.2. Anticoagulants
9.7.3. Diuretics
9.7.4. Anticonvulsants
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Haemorrhagic Stroke Drugs Demand Share Forecast, 2019-2026
10. Latin America Haemorrhagic Stroke Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
10.7.1. Antihypertensives
10.7.2. Anticoagulants
10.7.3. Diuretics
10.7.4. Anticonvulsants
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Haemorrhagic Stroke Drugs Demand Share Forecast, 2019-2026
11. Europe Haemorrhagic Stroke Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
11.7.1. Antihypertensives
11.7.2. Anticoagulants
11.7.3. Diuretics
11.7.4. Anticonvulsants
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Haemorrhagic Stroke Drugs Demand Share, 2019-2026
12. Asia Pacific Haemorrhagic Stroke Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
12.7.1. Antihypertensives
12.7.2. Anticoagulants
12.7.3. Diuretics
12.7.4. Anticonvulsants
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Haemorrhagic Stroke Drugs Demand Share, 2019-2026
13. Middle East & Africa Haemorrhagic Stroke Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Haemorrhagic Stroke Drugs Market Size and Volume Forecast by Type
13.7.1. Antihypertensives
13.7.2. Anticoagulants
13.7.3. Diuretics
13.7.4. Anticonvulsants
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Haemorrhagic Stroke Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Haemorrhagic Stroke Drugs Market: Market Share Analysis
14.2. Haemorrhagic Stroke Drugs Distributors and Customers
14.3. Haemorrhagic Stroke Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxter
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
